PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that its drug Besremi (ropeginterferon alfa-2b) has been approved by the National Medical Products Administration (NMPA) to treat adult polycythemia vera (PV) in China. This ultra-long-acting interferon, developed in-house, is already registered in the European Union, the US, Japan, South Korea, Taiwan, Macau, and 31 other countries and regions, totaling 38 markets.
Besremi is a novel, ultra-long-acting single polyethylene glycol proline interferon, featuring an additional N-terminal proline covalently modified by a 40kDa polyethylene glycol (PEG) group. The product allows for a maximum dosage of up to 500μg per dose, with a high maximum tolerable dose. The effective ingredients in a single dose of Besremi are dozens of times higher than those found in other long-acting interferons, while adverse reactions are reported to be low. The product is administered once every 2-4 weeks, significantly enhancing the convenience of medication for PV patients.- Flcube.com
